Real-world outcomes of caucasians with EGFR -mutated non-small-cell lung cancer treated with surgery (EXERPOS-2 GFPC study)
Therapeutic Advances in Medical Oncology · 2026-10 · 18
DOI: 10.1177/17588359261502422 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 28.10.2026. Verfasst von Jean-Bernard Auliac und 18 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: astra zeneca.
Abstract (Originalsprache)
Background
Little is known about the natural history of epidermal growth factor receptor ( EGFR) -mutated non-small-cell lung cancer (NSCLC) in Caucasian patients treated with surgery before the generalization of adjuvant treatment with osimertinib.
Objectives
The primary objective of this study was to describe the outcomes of such patients and their relapse modalities.
Design
French multicenter retrospective study.
Methods
Consecutive patients with early-stage EGFR -mutated NSCLCs, treated surgically between January 2018 and December 2020, were included in the analysis; osimertinib became available as adjuvant therapy in France in 2022. The following information was collected: patient characteristics, type of surgery, disease-free survival (DFS), progression modalities and overall survival (OS).
Results
The 291 patients analyzed were managed in 17 centers: median age: 70 (IQR: 34–85) years, 69% female, 78% never smokers, 99% adenocarcinoma, with 36% and 41% of them having exon19 or L858R mutations, respectively. Surgical resections were predominantly lobectomy (84%) and segmentectomy (12%), with 97% having complete lymph-node dissection; 96% of resections were R0. Post-surgery stages were deemed I, II and III, respectively, in 61%,18% and 21%; 82/291 (28%) patients received adjuvant treatment, 50/291 (17%) chemotherapy, 28/291 (9.6%) an EGFR-tyrosine-kinase inhibitor. After median follow-up of 35 (95% CI 16–82) months, disease progressed in 89/291 (30.5%) patients: stage I, II and III, respectively, 32/178 (18%), 22/52 (42%) and 35/61 (58%). Their respective 2- and-3-year DFS rates were 79% and 68%. DFS was not reached (NR) for stage I but lasted 41 (95% CI 41–NR) and 29 (95% CI 23-44) months for stages II and III. Two- and 3- year OS rates were 94% and 90%, respectively.
Conclusion
In conclusion, in the absence of adjuvant therapy, around 30% of patients with surgically resected EGFR -mutated NSCLCs had poor outcomes .
Förderung
- astra zeneca
Zitieren
APA
Auliac, J., Thomas, P., Bylicki, O., Guisier, F., Curcio, H., Vergnenègre, A., Swalduz, A., Wislez, M., Treut, J. L., Decroisette, C., Basse, V., Falchero, L., Chabot, G. D., Moreau, D., Huchot, E., Lupo, A., Blons, H., Chouaïd, C., & Greillier, L. (2026). Real-world outcomes of caucasians with EGFR -mutated non-small-cell lung cancer treated with surgery (EXERPOS-2 GFPC study). Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261502422
Vancouver
Auliac J, Thomas P, Bylicki O, Guisier F, Curcio H, Vergnenègre A, et al. Real-world outcomes of caucasians with EGFR -mutated non-small-cell lung cancer treated with surgery (EXERPOS-2 GFPC study). Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261502422
BibTeX
@article{Auliac2026,
author = {Auliac, Jean-Bernard and Thomas, Pascal-Alexandre and Bylicki, Olivier and Guisier, Florian and Curcio, Hubert and Vergnenègre, Alain and Swalduz, Aurelie and Wislez, Marie and Treut, Jacques Le and Decroisette, Chantal and Basse, Victor and Falchero, Lionel and Chabot, Gonzague De and Moreau, Diane and Huchot, Eric and Lupo, Audrey and Blons, Hélène and Chouaïd, Christos and Greillier, Laurent},
title = {Real-world outcomes of caucasians with EGFR -mutated non-small-cell lung cancer treated with surgery (EXERPOS-2 GFPC study)},
journal = {Therapeutic Advances in Medical Oncology},
year = {2026},
volume = {18},
doi = {10.1177/17588359261502422}
}
EUVIMED